Ardelyx to Participate at the Jefferies Global Healthcare Conference in London
WALTHAM, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that management will participate in a fireside chat at the Jefferies Global Healthcare Conference in London on Wednesday, November 19, 2025 at 4:30 pm GMT/11:30 am ET.
To access the live webcast of the panel presentation please visit the Events and Presentations page within the Ardelyx website at . A replay of the fireside chat will be available on the Ardelyx website for 30 days following the event.
About Ardelyx
Ardelyx was founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs. Ardelyx has two commercial products approved in the United States, IBSRELA® (tenapanor) and XPHOZAH® (tenapanor) as well as early-stage pipeline candidates. The company is developing RDX10531, a next-generation NHE3 inhibitor with potential application across multiple therapeutic areas. Ardelyx has agreements for the development and commercialization of tenapanor outside of the U.S. Kyowa Kirin commercializes PHOZEVEL® (tenapanor) for hyperphosphatemia in Japan. A New Drug Application for tenapanor for hyperphosphatemia has been approved in China with Fosun Pharma. Knight Therapeutics commercializes IBSRELA in Canada. For more information, please visit and connect with us on , and .
Investor and Media Contacts:
Caitlin Lowie
